Effects of Hirudin and Heparin on the Binding of New Fibrin to the Thrombus in t-PA Treated Rabbits

Summary

The aim of this study was to compare the ability of heparin and recombinant hirudin (r-hirudin) in preventing accretion of new fibrin on thrombi during and after treatment with tissue-type plasminogen activator (t-PA) and in enhancing t-PA induced fibrinolysis in a rabbit jugular vein thrombosis model. Heparin and r-hirudin were infused at doses capable of doubling aPTT. In the fibrin accretion inhibition experiments t-PA was infused over 3 h at a dose of 0.2 mg/kg along with saline or heparin, 0.75 mg/ kg or r-hirudin, 1.25 mg/kg. In rabbits treated with t-PA plus saline, heparin or r-hirudin, an accumulation of ¹²⁵I-fibrinogen on the thrombi of 52.5 ±5.1 εg, 49.5 ± 5.6 εg and 23.5 ± 3.5 εg was observed, respectively, the difference between r-hirudin and both saline and heparin being statistically significant (p <0.01). The inhibition of fibrin accretion on the thrombi induced by r-hirudin persists for at least 9 h after the end of the infusion. By that time r-hirudin has been cleared from the circulation and aPTT has returned to the baseline level for at least 8 h. t-PA, 0.2, 0.4, and 1 mg/kg, infused with saline produced 34 ± 6%, 52 ± 5% and 79 ± 8% lysis of pre-formed thrombi, respectively. The same doses of t-PA infused with heparin, 0.75 mg/kg, produced 32 ± 3%, 54 ± 5% and 78 ± 6% fibrinolysis, respectively and infused with r-hirudin, 1.25 mg/kg, 38 ± 3%, 57 ± 5% and 82 ± 8%, respectively. Thus, no differences in fibrinolysis were observed among the groups of rabbits treated with heparin, r-hirudin and saline receiving the same dose of t-PA. When thrombolysis was assessed by thrombus weight treatment with t-PA and r-hirudin was more effective than treatment with t-PA and saline or heparin. The positive effects of r-hirudin on t-PA induced thrombolysis we observed deserve to be confirmed in clinical settings.

• References

• 1 Verstraete M, Bernard R, Bory M, Brower RW, Collen D, De Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Uebis R, von Essen R. Randomised trial of intravenous recombinant tissue-type plasminogen, activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; i: 842-7
• 2 Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-54
• 3 Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. ASSET Lancet 1988; ii: 525-30
• 4 Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G. Six- and twelve-month follow-up of the phase I thrombolysis in myocardial infarction (TIMI) trial. Am J Cardiol 1988; 62: 179-88
• 5 Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583-7
• 6 Stassen JM, Juhan-Vague I, Alessi MC, De Cock F, Collen D. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemostas 1987; 58: 947-50
• 7 Topol EJ, George BS, Kereiakes DJ, Stump DC, Candel RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM. the TAMI Study Group A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-6
• 8 Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-7
• 9 Agnelli G, Pascucci C, Cosmi B, Nenci GG. Failure of therapeutic doses of heparin to improve thrombolysis with tissue-type plasminogen activator in rabbits. Blood 1990; 76: 2030-6
• 10 Francis CW, Markham RE, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-30
• 11 Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition of heparin and hirudin of coagulation activation during rt-PA induced thrombolysis. Blood 1989; 74: 1025-30
• 12 Kaplan K, Davison R, Parker M, Mayberry B, Feieresel P, Salinger M. Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1987; 59: 241-9
• 13 Heras M, Chesebro JH, Penny WJ, Bailey KR, Lam JYT, Holmes DR, Reeder GS, Badimon L, Fuster V. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988; 78: 654-61
• 14 Markwrdt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemostas 1989; 15: 269-82
• 15 Meyhack B, Heim J, Rink H, Zimmerman W, Marki W. Desulphato hirudin, a specific thrombin inhibitor: 33.
• 16 Grossenbacher H, Auden J, Bill K, Liersch M, Marki W. Isolation and characterization of recombinant desulfato hirudin from yeast: 34.
• 17 Talbot MD, Ambler J, Butler KD, Findlay VS, Mitchell KA, Peters RF, Tweed MF, Wallis RB. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemostas 1989; 61: 77-80
• 18 Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemostas 1990; 63: 204-7
• 19 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemostas 1987; 58: 1078-84
• 20 Agnelli G, Buchanan MR, Fernandez F, Boneu B, Van Ryn J, Hirsh J, Collen D. A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 1985; 72: 178-82
• 21 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46
• 22 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic Peptide Substances.. Scully M. (ed) Churchill Livingstone, Edinburgh: 1979. pp 128-39
• 23 Teger-Nielsson AC, Frieberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Lab Invest 1977; 37: 403-9
• 24 Teien AN, Lie M, Abilgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-8
• 25 Spannagl M, Bichler J, Lill H, Schramm W, Fritz H. A fast chromogenic assay for determination of hirudin in plasma. Thromb Haemostas 1989; 62: 328
• 26 Eisenberg PR, Sherman L, Rich M, Schwartz D, Schechtman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 1: 1255-62
• 27 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-20
• 28 Eisenberg PR, Sherman IA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10: 527-9
• 29 Seitz R, Blanke H, Pratorius G, Strauer GE, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemostas 1988; 59: 541-2
• 30 Heras M, Chesebro JH, Thompson PL, Fuster V. Prevention of early and late rethrombosis and further strategies after coronary reperfusion. In: Thrombolysis and Cardiovascular Diseases.. Julian D, Kubier W, Norris RM, Swan HJC, Collen D, Verstraete M. (eds) Dekker, New York: 1989. pp 203-29
• 31 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest 1990; 86: 385-91
• 32 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Biochemistry 1989; 86: 3619-23
• 33 Weitz JI, Cruickshank MK, Thong B, Leslie B, Levine MN, Ginsberg J, Eckhardt T. Human tissue-type plasminogen activator releases fibrinopeptidase A and B from fibrinogen. J Clin Invest 1988; 82: 1700-7
• 34 Krishnaswamy S, Mann KG, Nesheim ME. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem 1986; 261: 8977-84
• 35 Môrki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudins. Thromb Haemostas 1990; 64: 344-8
• 36 Hirsh J, Ofosu FA, Levine M. The development of low molecular weight heparin for clinical use. In: Thrombosis and Haemostasis.. Verstraete M, Vermylen J, Lijnen R, Arnout V. (eds) Leuven University Press, Leuven: 1987. pp 325-48